AbbVie Past Earnings Performance
Past criteria checks 1/6
AbbVie has been growing earnings at an average annual rate of 1%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 9.3% per year. AbbVie's return on equity is 84.5%, and it has net margins of 9.1%.
Key information
1.0%
Earnings growth rate
-2.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 9.3% |
| Return on equity | 84.5% |
| Net Margin | 9.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
AbbVie: Upgrading To 'Strong Buy' After Pullback
Nov 22AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64
Nov 19
AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear
Nov 12AbbVie Stock: Keep Calm And Buy The Dip
Nov 11AbbVie: 3 Positives From The Earnings Report
Oct 30AbbVie: Strong Dividends But Humira Disappoints
Oct 22AbbVie: Dividend Discount Model Suggests Large Valuation Risks
Sep 29We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt
Sep 06Why AbbVie Remains One Of My Favorite Dividend Growers
Aug 27AbbVie: Growth Is Still A Better Choice
Jul 29AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note
Jul 17AbbVie: A Hold Again (Rating Downgrade)
Jul 03Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)
Jun 28AbbVie: 5 Reasons That Make A Buy Case
Jun 18Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
May 29Revenue & Expenses Breakdown
How AbbVie makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 55,533 | 5,081 | 13,865 | 7,755 |
| 30 Jun 24 | 55,000 | 5,298 | 13,134 | 7,405 |
| 31 Mar 24 | 54,403 | 5,951 | 12,973 | 7,189 |
| 31 Dec 23 | 54,318 | 4,820 | 12,904 | 7,038 |
| 30 Sep 23 | 55,138 | 6,471 | 12,453 | 6,897 |
| 30 Jun 23 | 56,023 | 8,635 | 12,260 | 6,785 |
| 31 Mar 23 | 56,741 | 7,535 | 12,201 | 6,661 |
| 31 Dec 22 | 58,054 | 11,782 | 12,084 | 6,487 |
| 30 Sep 22 | 57,819 | 13,343 | 12,116 | 6,518 |
| 30 Jun 22 | 57,349 | 12,569 | 11,988 | 6,551 |
| 31 Mar 22 | 56,725 | 12,407 | 11,943 | 6,692 |
| 31 Dec 21 | 56,197 | 11,468 | 11,872 | 6,820 |
| 30 Sep 21 | 55,169 | 7,465 | 11,054 | 6,829 |
| 30 Jun 21 | 53,729 | 6,599 | 10,860 | 6,761 |
| 31 Mar 21 | 50,195 | 5,092 | 10,955 | 6,418 |
| 31 Dec 20 | 45,804 | 4,556 | 9,867 | 6,003 |
| 30 Sep 20 | 40,650 | 7,324 | 9,429 | 5,902 |
| 30 Jun 20 | 36,227 | 6,906 | 8,288 | 5,582 |
| 31 Mar 20 | 34,057 | 8,395 | 6,760 | 5,467 |
| 31 Dec 19 | 33,266 | 7,842 | 6,763 | 5,377 |
| 30 Sep 19 | 32,867 | 3,232 | 6,487 | 5,260 |
| 30 Jun 19 | 32,624 | 4,093 | 6,765 | 5,273 |
| 31 Mar 19 | 32,647 | 5,333 | 6,873 | 5,304 |
| 31 Dec 18 | 32,753 | 5,657 | 7,353 | 5,259 |
| 30 Sep 18 | 32,187 | 7,531 | 6,972 | 5,242 |
| 30 Jun 18 | 30,946 | 6,419 | 6,623 | 5,202 |
| 31 Mar 18 | 29,612 | 6,352 | 6,303 | 5,109 |
| 31 Dec 17 | 28,216 | 5,283 | 6,248 | 5,007 |
| 30 Sep 17 | 27,273 | 6,615 | 5,958 | 4,789 |
| 30 Jun 17 | 26,710 | 6,582 | 5,799 | 4,667 |
| 31 Mar 17 | 26,218 | 6,278 | 5,861 | 4,562 |
| 31 Dec 16 | 25,638 | 5,923 | 5,837 | 4,385 |
| 30 Sep 16 | 25,242 | 6,048 | 5,733 | 4,178 |
| 30 Jun 16 | 24,754 | 5,690 | 5,724 | 4,472 |
| 31 Mar 16 | 23,777 | 5,448 | 5,646 | 4,236 |
| 31 Dec 15 | 22,859 | 5,118 | 5,663 | 4,101 |
| 30 Sep 15 | 21,911 | 2,790 | 6,059 | 3,978 |
| 30 Jun 15 | 20,986 | 2,064 | 6,178 | 3,390 |
| 31 Mar 15 | 20,437 | 1,802 | 6,133 | 3,336 |
| 31 Dec 14 | 19,960 | 1,765 | 6,024 | 3,297 |
| 30 Sep 14 | 19,619 | 3,686 | 5,413 | 3,201 |
| 30 Jun 14 | 19,258 | 4,144 | 5,136 | 3,103 |
| 31 Mar 14 | 19,024 | 4,114 | 5,113 | 2,978 |
| 31 Dec 13 | 18,790 | 4,102 | 5,352 | 2,840 |
Quality Earnings: ABBV has a large one-off loss of $8.4B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: ABBV's current net profit margins (9.1%) are lower than last year (11.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABBV's earnings have grown by 1% per year over the past 5 years.
Accelerating Growth: ABBV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ABBV had negative earnings growth (-21.5%) over the past year, making it difficult to compare to the Biotechs industry average (16.6%).
Return on Equity
High ROE: Whilst ABBV's Return on Equity (84.55%) is outstanding, this metric is skewed due to their high level of debt.